> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By Steve Moore | Thursday 7 June 2018
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Tissue products manufacturing group Accrol (ACRL) has updated that it received valid applications of 287.64% of the new shares available under an open offer to raise up to £1.935 million at 15p per share. That compares with a 22.5p prior close, but also more than 130p as recently as October 2017, so where now?
The noted open offer take-up will see excess applications “satisfied on a basis that takes account of their respective holdings of shares in the company as at 5.00 p.m. on 18 May 2018” - and the total of 12,901,200 new shares to be issued under the open offer will see the issued share capital to 195,246,536 shares.
That compares to 93,012,002 on June 2016, 100p per share, AIM admission, when the company emphasised “the net proceeds… will be used by the group to repay all shareholder loan notes and refinance existing debt… believe that admission will provide the business with an increased reputation and profile and the ability to incentivise key employees, as well as providing a platform for the group to execute its strategy”. It has subsequently been;
However, that latest placing announcement still included “the net debt position of the company on admission, taking into account the net proceeds of the placing of c.£7.5 million, is expected to be c.£25.5 million” and “the directors believe, having taken into account the net proceeds of the placing, that the group will have sufficient working capital for its short term requirements. However, the board is unable to make any confirmations about the sufficiency of working capital beyond this due to the group's working capital being highly sensitive to, amongst other things, Parent Reel pricing, foreign exchange fluctuations, the level of turnover and the pace of progress on the group's ongoing operational restructuring”.
Hmmm. AIM admission to refinance debt, provide an increased reputation and profile, incentivise key employees and provide a platform to execute strategy hey! What price would ANOTHER bailout have to be? This thus currently remains another tale of AIM IPO shame (thanks AGAIN Zeus Capital!) on the bargepole list.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments are turned off for this article.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen